200 related articles for article (PubMed ID: 28993206)
41. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis.
Zhao C; Irie N; Takada Y; Shimoda K; Miyamoto T; Nishiwaki T; Suda T; Matsuo K
Cell Metab; 2006 Aug; 4(2):111-21. PubMed ID: 16890539
[TBL] [Abstract][Full Text] [Related]
42. EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Becerikli M; Merwart B; Lam MC; Suppelna P; Rittig A; Mirmohammedsadegh A; Stricker I; Theiss C; Singer BB; Jacobsen F; Steinstraesser L
Int J Cancer; 2015 Apr; 136(8):1781-91. PubMed ID: 25274141
[TBL] [Abstract][Full Text] [Related]
43. Ephrin‑B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis‑free survival in breast cancer.
Magic Z; Sandström J; Perez-Tenorio G
Int J Oncol; 2019 Dec; 55(6):1275-1286. PubMed ID: 31638179
[TBL] [Abstract][Full Text] [Related]
44. Communication between ephrinB2 and EphB4 within the osteoblast lineage.
Martin TJ; Allan EH; Ho PW; Gooi JH; Quinn JM; Gillespie MT; Krasnoperov V; Sims NA
Adv Exp Med Biol; 2010; 658():51-60. PubMed ID: 19950015
[TBL] [Abstract][Full Text] [Related]
45. Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4.
Stephenson SA; Douglas EL; Mertens-Walker I; Lisle JE; Maharaj MS; Herington AC
Oncotarget; 2015 Apr; 6(10):7554-69. PubMed ID: 25831049
[TBL] [Abstract][Full Text] [Related]
46. The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment.
Buckens OJ; El Hassouni B; Giovannetti E; Peters GJ
Expert Opin Investig Drugs; 2020 Jun; 29(6):567-582. PubMed ID: 32348169
[TBL] [Abstract][Full Text] [Related]
47. Structural and biophysical characterization of the EphB4*ephrinB2 protein-protein interaction and receptor specificity.
Chrencik JE; Brooun A; Kraus ML; Recht MI; Kolatkar AR; Han GW; Seifert JM; Widmer H; Auer M; Kuhn P
J Biol Chem; 2006 Sep; 281(38):28185-92. PubMed ID: 16867992
[TBL] [Abstract][Full Text] [Related]
48. PSGL-1-mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cells.
Foubert P; Silvestre JS; Souttou B; Barateau V; Martin C; Ebrahimian TG; Leré-Déan C; Contreres JO; Sulpice E; Levy BI; Plouët J; Tobelem G; Le Ricousse-Roussanne S
J Clin Invest; 2007 Jun; 117(6):1527-37. PubMed ID: 17510705
[TBL] [Abstract][Full Text] [Related]
49. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome.
Brantley-Sieders DM; Jiang A; Sarma K; Badu-Nkansah A; Walter DL; Shyr Y; Chen J
PLoS One; 2011; 6(9):e24426. PubMed ID: 21935409
[TBL] [Abstract][Full Text] [Related]
50. EphrinB2-EphB4-RASA1 Signaling in Human Cerebrovascular Development and Disease.
Zeng X; Hunt A; Jin SC; Duran D; Gaillard J; Kahle KT
Trends Mol Med; 2019 Apr; 25(4):265-286. PubMed ID: 30819650
[TBL] [Abstract][Full Text] [Related]
51. The ephrins and Eph receptors in angiogenesis.
Cheng N; Brantley DM; Chen J
Cytokine Growth Factor Rev; 2002 Feb; 13(1):75-85. PubMed ID: 11750881
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of tumor growth and angiogenesis by soluble EphB4.
Martiny-Baron G; Korff T; Schaffner F; Esser N; Eggstein S; Marmé D; Augustin HG
Neoplasia; 2004; 6(3):248-57. PubMed ID: 15153337
[TBL] [Abstract][Full Text] [Related]
53. Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue.
Ozgür E; Heidenreich A; Dagtekin O; Engelmann U; Bloch W
Urol Oncol; 2011; 29(1):78-84. PubMed ID: 19272799
[TBL] [Abstract][Full Text] [Related]
54. EphB4 Regulates Self-Renewal, Proliferation and Neuronal Differentiation of Human Embryonic Neural Stem Cells in Vitro.
Liu T; Zeng X; Sun F; Hou H; Guan Y; Guo D; Ai H; Wang W; Zhang G
Cell Physiol Biochem; 2017; 41(2):819-834. PubMed ID: 28214829
[TBL] [Abstract][Full Text] [Related]
55. EphrinB2/EphB4 pathway in postnatal angiogenesis: a potential therapeutic target for ischemic cardiovascular disease.
Yang D; Jin C; Ma H; Huang M; Shi GP; Wang J; Xiang M
Angiogenesis; 2016 Jul; 19(3):297-309. PubMed ID: 27216867
[TBL] [Abstract][Full Text] [Related]
56. Targeting Eph receptors with peptides and small molecules: progress and challenges.
Noberini R; Lamberto I; Pasquale EB
Semin Cell Dev Biol; 2012 Feb; 23(1):51-7. PubMed ID: 22044885
[TBL] [Abstract][Full Text] [Related]
57. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells.
Füller T; Korff T; Kilian A; Dandekar G; Augustin HG
J Cell Sci; 2003 Jun; 116(Pt 12):2461-70. PubMed ID: 12734395
[TBL] [Abstract][Full Text] [Related]
58. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth.
Krasnoperov V; Kumar SR; Ley E; Li X; Scehnet J; Liu R; Zozulya S; Gill PS
Am J Pathol; 2010 Apr; 176(4):2029-38. PubMed ID: 20133814
[TBL] [Abstract][Full Text] [Related]
59. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
Mitchell SA; Danca MD; Blomgren PA; Darrow JW; Currie KS; Kropf JE; Lee SH; Gallion SL; Xiong JM; Pippin DA; DeSimone RW; Brittelli DR; Eustice DC; Bourret A; Hill-Drzewi M; Maciejewski PM; Elkin LL
Bioorg Med Chem Lett; 2009 Dec; 19(24):6991-5. PubMed ID: 19879134
[TBL] [Abstract][Full Text] [Related]
60. Regulation of signaling interactions and receptor endocytosis in growing blood vessels.
Pitulescu ME; Adams RH
Cell Adh Migr; 2014; 8(4):366-77. PubMed ID: 25482636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
